• Joaquim Bellmunt, Thian Kheoh, Margaret K Yu, Matthew R Smith, Eric J Small, Peter F A Mulders, Karim Fizazi, Dana E Rathkopf, Fred Saad, Howard I Scher, Mary-Ellen Taplin, Ian D Davis, Dirk Schrijvers, Andrew Protheroe, Arturo Molina, Peter De Porre, Thomas W Griffin, Johann S de Bono, Charles J Ryan, and Stéphane Oudard.
• Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Joaquim_Bellmunt@dfci.harvard.edu.
• Eur. Urol. 2016 May 1; 69 (5): 924-32.

BackgroundThe duration of prior hormonal treatment can predict responses to subsequent therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).ObjectiveTo determine if prior endocrine therapy duration is an indicator of abiraterone acetate (AA) sensitivity.Design, Setting, And ParticipantsPost-hoc exploratory analysis of randomised phase 3 studies examining post-docetaxel (COU-AA-301) or chemotherapy-naïve mCRPC (COU-AA-302) patients receiving AA. The treatment effect on overall survival (OS), radiographic progression-free survival (rPFS), and prostate-specific antigen (PSA) response analysed by quartile duration of prior gonadotropin-releasing hormone agonists (GnRHa) or androgen receptor (AR) antagonist.InterventionPatients were randomised to AA (1000mg, orally once daily) plus prednisone (5mg, orally twice daily) or placebo plus prednisone. Prior endocrine therapy was GnRHa (COU-AA-301, n=1127 [94%]; COU-AA-302, n=1057 [97%], 45.1 mo or 36.7 mo median duration, respectively) and/or orchiectomy (COU-AA-301, n=78 [7%] COU-AA-302, n=44 [4%]); castrated patients received prior AR antagonists (COU-AA-301, n=1015 [85%]; COU-AA-302, n=1078 [99%], 15.7 mo or 16.1 mo median duration, respectively).Outcome Measurements And Statistical AnalysisCox model was used to obtain hazard ratio and associated 95% confidence interval with statistical inference by log rank statistic.Results And LimitationsClinical benefit with AA was observed for OS, rPFS, and PSA response for nearly all quartiles with GnRHa or AR antagonists in both COU-AA-301 and COU-AA-302. In COU-AA-301, patients with a longer duration of prior endocrine therapy tended to have greater AA OS, rPFS, and PSA response benefit, with lead-time chemotherapy bias potentially impacting COU-AA-301 results. Time to castration resistance was not captured. This analysis is limited as a post-hoc exploratory analysis.ConclusionsIn the COU-AA-301 and COU-AA-302 studies, AA produced clinical benefits regardless of prior endocrine therapy duration in patients with mCRPC.Patient SummaryMetastatic castration-resistant prostate cancer patients derived clinical benefits with abiraterone acetate regardless of prior endocrine therapy duration.Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

34 keywords...

hide…